ORIGINAL ARTICLE: PDF OnlyPhase II Study of Aminothiadiazole in Advanced Squamous Cell Carcinoma of the EsophagusEngstrom, Paul F., M.D.; Ryan, Louise M., Ph.D.; Falkson, Geoffrey, M.D.; Haller, Daniel G., M.D.Author Information Fox Chase Cancer Center, Philadelphia, Pennsylvania (P.F.E.); Dana-Farber Cancer Institute, Harvard School of Public Health, Boston, Massachusetts (L.M.R.); the University of Pretoria, Pretoria, South Africa (G.F.); and the Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania (D.G.H.). American Journal of Clinical Oncology: February 1991 - Volume 14 - Issue 1 - p 33-35 Buy Abstract Twenty-three patients with advanced inoperable squamous cell carcinoma of the esophagus were treated with amino-thiadiazole (A-TD) 125 mg/m2 weekly plus allopurinol daily in a phase II cooperative group trial. No patients responded to treatment; 17 patients progressed, three showed stable disease, and three were unevaluable. There were no life-threatening hematologic or metabolic toxicities. The median survival from study entry was 5 months. A-TD is not active in advanced squamous cell carcinoma of the esophagus. © Lippincott-Raven Publishers.